Naratriptan (NAR) is currently used as the hydrochloride salt (NAR.HCl) for the treatment of migraine and is available in tablet dosage forms for oral administration.
Introduction
Migraine is a neurological syndrome of severe headache described as a throbbing pain in the front or one half of the head and may be associated with nausea and light sensitivity (Davidoff, 2002) . It is a major public health problem and it affects over 20% of people at some stage in their lives; studies have shown that 4.5% of the population of Western Europe experiences headache a minimum of 15 days on average per month (Welch and Goadsby, 2002) . Global studies indicate that up to 1% of the population worldwide may have chronic migraine (Natoli et al., 2010) . The condition is accompanied by substantial personal suffering and disability and also has implications for economic output and productivity (Smitherman et al., 2013) . There is currently no cure for migraine and the therapy is complicated by the different outcomes among, and within, individual patients and by the limited understanding of the pathophysiology of the syndrome (Brunton and Parker, 2008) .
Triptans are indole derivatives that are used in the first-line management of migraines that do not respond to combination analgesics (Loder, 2010) . Amotriptan, eletriptan, frovatriptan, naratriptan, and rizatriptan, are currently administered as oral tablet dosage forms. Sumatriptan is available as an oral tablet form and as an intra-nasal spray preparation. Zolmitriptan is formulated in three dosage forms: a conventional tablet, an oral disintegrating tablet and a nasal spray. These three zolmitriptan dosage forms were evaluated for patient preferences by Dowson et al. (2007) . Initially the majority of patients preferred conventional oral tablets. After 4 months, 46.9% and 43.8% expressed preferences for the oral disintegrating tablet and the nasal spray respectively while only 6.3% preferred the ordinary tablet. The authors concluded that speed and efficacy of the migraine formulation were the key factors that influenced patient preferences.
Few publications have reported on the buccal or oral transmucosal route for delivery of triptans. This is surprising given that this mode of administration bypasses first pass metabolism and generally results in faster systemic delivery compared with conventional oral delivery (Sattar et al., 2014) . Based on potency and physicochemical properties we have previously identified naratriptan (NAR) as a potential candidate for buccal delivery. We also reported the preparation and characterization of NAR base from NAR.HCl. Finally, we demonstrated that the base has more favourable properties than the salt for oral transmucosal delivery using in vitro studies in porcine buccal tissue (Sattar et al., 2015) . The aims of the present work were to (i) evaluate a range of single and binary solvent vehicles for optimal buccal delivery of NAR and (ii) examine the mechanisms of action of vehicle components on NAR permeation. The solvents investigated in the present work were selected to span a range of NAR solubility values, based on data reported in our previous publication (Sattar et al., 2015) .
Materials and Methods

Materials
Naratriptan HCl (NAR.HCl) was obtained from Bioprogress (March, UK) and NAR base was prepared as described previously (Sattar et al., 2015 
Methods
Preparation of liquid dosage forms and solubility determination
The preparation of liquid dosage forms was conducted by dissolving a known amount of NAR base in the required volume of solvent(s). A range of single and binary systems were prepared using TC, PG, DPG, OA, PEG 200, PEG 400, and MG. The recommended NAR dose is 2.5 mg per attack with a maximum daily dose of 5 mg (Joint Formulary Committee, 2014) . The concentration of NAR was therefore selected to give a final dosage of 2.5 mg per 100 l application, with the exception of MG. A saturated solution of NAR in MG was prepared because of the low solubility of the molecule in this solvent. Solubility data for all neat solvents are reported in our previous publication (Sattar et al., 2015) .
Miscibility studies
To identify appropriate binary solvent systems miscibility studies were carried out at room temperature. Appropriate proportions of solvents were carefully mixed in a glass test tube to a final volume of 3 mL, left to stand and observed after 24 h. Mixtures were considered to be miscible only after a clear and transparent solution was visualized.
In vitro permeation and mass balance studies
Permeation experiments were conducted as reported previously (Sattar et al., 2015) with porcine buccal tissue obtained from a local abattoir. A dermatome (Padgett instruments ® , USA) was used to ensure uniform membrane thickness (0.8 ± 0.1 mm). The tissue was cut to suitable dimensions and mounted in Franz diffusion cells with effective diffusional areas of ~1 cm 2 and the area for each cell was measured accurately as detailed previously (Oliveira et al., 2012) . Permeation studies were conducted with caffeine to confirm the integrity of all tissues (data not shown) as reported in our previous publication (Sattar et al., 2015) . The receptor phase was PBS (pH 7.4) and 1 mL of PBS was added to the donor chamber for 30 min to ensure tissue hydration. The solubility of NAR in PBS was 1.1 mg/mL and sink conditions were maintained during the experiment.
The temperature of the cells was measured at regular intervals with a thermometer (Corby, UK) until all cells were equilibrated at 37 ± 0.5ºC. Permeation experiments were conducted under occlusion by covering the donor compartments with Parafilm ™ . An aliquot of 200 µL was withdrawn from each receptor chamber at specific time intervals and replaced with an equal amount of warm fresh degassed PBS. Samples were analysed by HPLC (Sattar et al., 2015) and the number of assays conducted each sample was n>3. The cumulative amount of drug permeated per unit area of buccal mucosa (µg/cm 2 ) was plotted against the collection time (min) using Excel 2010 (Microsoft, USA) as reported previously. The slope of this graph at the steady state was considered as the flux (Jss) and the extrapolated x-axis intercept as the lag time (tlag) as reported by Watkinson et al. (2010) . The cumulative amount/area (Qn) at time (n) was determined and the permeability coefficient (kp) was calculated from Jss as reported in our previous publication (Sattar et al., 2015) .
At the end of the permeation experiment the residual formulation in the donor chamber was removed, diluted and NAR was analysed by HPLC (Sattar et al., 2015) . The surface of the membrane was washed three times with 1 mL of methanol:water (50:50, v/v). Finally, the cells were disassembled and the buccal membranes were cut into small pieces and incubated in 5 mL of methanol:water (50:50, v/v) at 37ºC with shaking to extract the drug inside the tissue. The buccal washes and extracts were centrifuged for 20 min at 13.2 (×1000) rpm (Eppendorf centrifuge, UK) and a sample of the supernatant was diluted and analysed by HPLC (Sattar et al., 2015) . The final cumulative amount of drug permeated was used to calculate the recovery of the drug in the receptor phase. Method validation for the mass balance studies has also been reported in our previous publication. .
Gas Chromatography (GC) analysis
TC was analysed using a gas chromatography instrument (Agilent 7890A, USA)
equipped with a flame ionisation detector and operated by ChemStation ® for GC systems software. A stock solution of 100 µmol/mL of TC in water was used to prepare a series of concentrations ranging from 0.1-14.7 µmole/mL. Analyses were performed on a Zebron™ ZB-WAX column (30 m × 0.5 mm × 0.1 µm; Phenomenex, USA). The chromatographic conditions were as follows: Nitrogen was used as a carrier gas at a flow rate of 6.6 mL/min. The injection volume was 0.5 µL with a 1:1 split ratio with nitrogen and an inlet temperature of 225°C. The column was operated under the following gradient mode: the oven starting temperature was set at 80°C and this was increased to 215°C at a rate of 15°C/min with a total run time of 9 min. The detector temperature was set at 300°C and the retention time of TC was ~5.48 min. The method was validated in terms of specificity, linearity, accuracy, precision, detection limit (LOD) and quantification limit (LOQ) according to the International Conference of Harmonization guidelines (ICH, 2005) . The values for LOD and LOQ were 0.26 mol/mL and 0.79 mol/mL respectively.
Statistical analysis
All data were analysed using SPSS version 22 and Excel (Microsoft Office 2010).
The results are presented as mean ± standard deviation (SD). The Student's t-test and oneway ANOVA with replication using the Post Hoc Tukey test were used to investigate statistical differences. A probability of p < 0.05 was considered statistically significant.
Results and Discussion
Permeation from single solvents
The steady state flux (Jss), lag time (tlag), permeability coefficient (kp) and amount of NAR permeated after 6 h (Q6h) for all single solvents studied are shown in Table 1 .
NAR permeated to the highest extent from TC followed by DPG, PG, PEG 200 and PEG 400, respectively. When formulated in OA only 0.1% of the applied dose of the drug had permeated by the end of the experiment. When NAR was prepared as a solution in Transcutol P ® the maximum buccal flux was observed (~2.4 µg/min/cm 2 ). As noted in our previous study (Sattar et al., 2015) , the solubility of NAR in the neat solvents may be ranked as follows: TC>DPG>PEG 200>PG=PEG 400> OA. This reflects the rank order for the flux values in Table 1 . The solubility of NAR in TC was determined to be 106 mg/mL at 37°C which was significantly higher than all other solvents studied (p<0.05).. TC is a common co-solvent which is used in oral, dermal, and parenteral pharmaceutical formulations (Strickley, 2004) . Previously, TC:water (50:50) was reported to enhance the buccal permeation of lidocaine hydrochloride by a factor of 2.3 compared with water alone (Ganem-Quintanar et al., 1998). The enhancement observed was attributed to the ability of TC to promote the partitioning of lidocaine hydrochloride into buccal tissue. Additionally, Ceschel and coworkers (2000) reported that the permeation of an essential oil through excised porcine buccal mucosa was significantly increased by incorporation of TC at 10 or 20% in a microemulsion-gel formulation. The enhancement was directly proportional to the TC concentration in the formulation. Although the exact mechanism by which TC promotes permeation is still unclear, some authors have suggested that it enhances drug solubility in epithelial membranes. Puglia and Bonina (2008) studied the enhancement effect of TC on the dermal absorption of atenolol in vitro, using human skin. These workers suggested that TC increases the apparent membrane-solvent partition coefficient of the molecule rather than the diffusion coefficient.
Glycols have been widely used in the enhancement of topical drug permeation but as for TC their enhancement mechanisms have not been elucidated fully. It has been suggested that increased drug solubility in skin results from the interaction of glycols with the polar head groups of lipid bilayers and their occupation of hydrogen binding sites (Lane, 2013) . NAR is more soluble in DPG (64 mg/mL) than PG (46 mg/mL) at 37°C (Sattar et al., 2015) , suggesting that as for TC, favourable solubility in this solvent is related to uptake and/or permeation into buccal tissue. Aqueous buffer solutions of PG (40% v/v) have been shown to promote effective buccal permeation of buspirone (Birudaraj et al., 2005) . PG is currently also included in a number of commercial buccal film formulations. As DPG has not been studied to the same extent as PG for buccal delivery the results here suggest that it should be investigated further for this application.
PEG 200 and PEG 400 are stable, hydrophilic substances, and are widely used in oral, parenteral, ophthalmic, topical, and rectal formulations. These specific PEG grades were selected because NAR exhibited good solubility in both at 37°C, namely 55 mg/mL in PEG 200 and 34 mg/mL in PEG 400 (Sattar et al., 2015) . Almost twice the amount of naratriptan permeated from PEG 200 compared with PEG 400 (t-test, p < 0.05). PEG 400 has also been shown to retard the buccal permeation of donazepil in a concentrationdependent manner (Caon et al., 2014) . This was attributed to a direct interaction between the drug and PEG 400 and its effects on the thermodynamic activity of the molecule.
OA has been reported to enhance the buccal permeation of buspirone and propranol when combined with PG (Manganaro and Wertz, 1996; Birudaraj et al., 2005) . Manganaro and Wertz (1996) proposed that the change in permeation may reflect the lipid fluidizing effects of OA, because of the presence of its cis-bond which disrupts lipid packing. However, the potential effects of PG in contributing to permeation via displacement of water molecules were also acknowledged by these authors. Birudaraj et al. (2005) postulated that OA enhances buccal permeation of buspirone via the transcellular pathway because of its ability to act as a penetration enhancer for transdermal delivery.
The failure of OA to enhance NAR delivery compared with the other solvents studied (Table 1 ) might reflect ionic complexation between the ternary amine group of naratriptan and the carboxylic group of OA. The reduction in the permeation of the basic drug, donepezil, through porcine buccal tissue in the presence of OA has been attributed to a similar interaction with OA (Caon et al., 2014) .
MG is a mixture of medium chain triglycerides of fractionated C8 (caprylic), C10
(capric) and C12 (lauric) fatty acids derived from coconut oil (Pouton and Porter, 2008) .
Because of the low solubility of NAR in MG, a saturated solution was prepared for buccal permeation studies. MG delivered around 16% of the applied dose, with a calculated flux of 0.08 ± 0.01 µg//cm 2 /min and a permeability coefficient of 95.4 ± 10.1 x10 -6 cm/min.
Interestingly, the lag time (97±5 min) was the shortest of all solvents evaluated, and the permeability coefficient was similar to that observed for the TC vehicle. MG has typically been used as a component of emulsion vehicles for oral or dermal delivery of actives (Sahle et al., 2013; Le Bars et al., 2015) . The use of MG as a potential excipient in buccal formulations does not appear to have been examined previously.
Permeation from binary systems of TC with PG, DPG or OA
Since NAR permeation was highest from TC, binary systems were prepared by combining this solvent with PG, DPG or OA in a 1:1 ratio. Binary systems of TC with PEG 200 or PEG 400 were not evaluated because of the low permeation obtained with PEG 400 and the comparable solubility values of NAR in PG and PEG 200. Permeation studies were subsequently conducted using the same dose and conditions as for the previous section. The permeability parameters and permeation profiles of NAR for these mixtures are shown in Table 2 . The highest and lowest values for NAR flux and permeation were observed for the TC:PG and TC:OA combinations respectively. Interestingly, the lowest lag time for NAR was also evident for the TC:OA, suggesting a faster interaction between this vehicle and the buccal membrane. OA has previously been suggested to fluidise intercellular lipids in skin (Francoeur et al., 1990) , but this has not been reported for buccal tissue The permeation parameters of NAR for the TC:PG system, namely; Jss, kp, and Q6h are significantly higher than the corresponding parameters for the TC:DPG and TC:OA systems (ANOVA, p < 0.05). These results may reflect the lower thermodynamic activity of NAR in the TC:DPG system compared with TC:PG, based on solubility in the neat solvents (Sattar et al., 2015) , and with reference to the TC:OA system, an interaction between OA and NAR, as discussed in Section 3.1.
NAR permeation from TC:PBS (pH 6.8) systems
To gain further insight into the buccal permeation enhancement properties of TC, binary mixtures of TC and PBS (pH 6.8) in different proportions were prepared (NAR 2.5 mg/100 µL) and permeation was evaluated. This pH was selected to simulate that of the oral cavity as saliva has a normal pH range of 6.2 -7.6 (Newman et al., 2014) . Mass balance studies were also conducted at the end of this set of experiments. As the minimum ratio of TC required to dissolve this amount of NAR was 50%, the binary systems tested contained TC at 50, 75, and 90%. Figures 1a and 1b show the corresponding permeation profiles and mass balance data for these vehicles. As shown in Figure 1 and Table 3 , for TC:PBS (50:50), values for Jss, Q6h, and amounts of NAR extracted from buccal membrane were decreased by 5, 4, and 2 fold, respectively, compared with values for neat TC (ANOVA, p < 0.05). NAR permeation from the TC:PBS binary systems increased with an increase in the TC proportion. At the same time, the percentage of NAR extracted from the buccal membrane at the end of the permeation experiment was also dependent on TC content. Accordingly, it is reasonable to hypothesise that TC may enhance the permeation of naratriptan through the porcine buccal mucosa by increasing drug uptake into tissue. This finding is also consistent with other studies whereby TC is proposed to act as a permeation enhancer by improving drug partitioning with biological membranes (Ganem-Quintanar et al., 1998; Ceschel et al., 2000; Puglia and Bonina, 2008) .
TC:PBS (pH
NAR and TC permeation from TC:MG vehicles
Formulations with TC with MG were also tested to examine how a binary mixture of solvents with variable solubility parameters might influence buccal permeation. Binary mixtures of TC and MG were prepared in the following proportions: 50:50, 75:25, 90:10.
The concentration of NAR and dose applied was the same as for the previous sections. 
Conclusions
The present study builds on our previous work which characterised NAR base and investigated its permeation in excised porcine buccal tissue. Initially, in vitro permeation of NAR was investigated in the same model from a range of simple solvents; the highest permeation was observed for TC which was the vehicle in which NAR was most soluble.
For binary systems, the combination of DPG, PG or TC did not result in significant enhancement of NAR permeation. A range of TC:PBS systems were subsequently evaluated for NAR delivery, where the pH of PBS was 6.8. As TC content increased so did NAR permeation; higher amounts of NAR were also extracted from tissue for systems 
